Fig. 3From: Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancerInvestigator-assessed progression-free survival among phase 2a patients. CI confidence interval, NE not estimable. + censored due to withdrawal or enrollment in the extension studyBack to article page